Wasenmiller J E, Aronow W S
Clin Pharmacol Ther. 1980 Oct;28(4):431-5. doi: 10.1038/clpt.1980.184.
The efficacy on premature ventricular contractions (PVCs) of tocainide 600 mg three times daily and of quinidine sulfate 300 mg four times daily administered for 8 wk versus placebo administered for 6 wk was determined in 41 patients. Neither the subjects nor the interpreter of the Holter recordings knew which medication had been used. Adverse effects occurred in 14 of 22 patients (64%) on tocainide and in nine of 19 (47%) on quinidine. Adverse effects caused 13 of 22 patients (59%) on tocainide and six of 19 (32%) on quinidine to discontinue medication. Reduction of PVCs greater than or equal to 75% over placebo occurred in one of nine patients (11%) on tocainide and in six of 13 (46%) on quinidine. By Lown's classification, a reduction in one grade of PVCs occured in two of nine patients (22%) on tocainide and in eight of 13 (62%) on quinidine. Neither tocainide nor quinidine has a high incidence of efficacy and a low incidence of adverse effects but, in the doses used, quinidine was more effective, benefited a larger proportion of patients, and induced fewer adverse effects than tocainide.
在41例患者中，确定了每日3次服用600毫克妥卡尼、每日4次服用300毫克硫酸奎尼丁，持续8周与服用安慰剂6周相比，对室性早搏（PVCs）的疗效。动态心电图记录的受试者和解读人员均不知道使用了哪种药物。服用妥卡尼的22例患者中有14例（64%）出现不良反应，服用奎尼丁的19例患者中有9例（47%）出现不良反应。不良反应导致服用妥卡尼的22例患者中有13例（59%）、服用奎尼丁的19例患者中有6例（32%）停药。与安慰剂相比，PVCs减少大于或等于75%的情况在服用妥卡尼的9例患者中有1例（11%）出现，在服用奎尼丁的13例患者中有6例（46%）出现。按照洛恩分级法，服用妥卡尼的9例患者中有2例（22%）PVCs降低一级，服用奎尼丁的13例患者中有8例（62%）出现这种情况。妥卡尼和奎尼丁的有效率都不高，不良反应发生率也不低，但在所使用的剂量下，奎尼丁比妥卡尼更有效，受益患者比例更大，不良反应更少。
